May 8th 2024
Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
Heading to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Medical Crossfire®: Exchange Between Onco-Nursing Experts on MPN Treatment and Symptom Management Along the Care Continuum
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Only 20% of Patients with Fibromyalgia Report Receiving Satisfactory Information on Pain
Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.